{"ticker": {"uuid": "7bcd943f-a41d-4e0c-ae1e-0b57f084282f", "symbol": "PLRZ", "name": "Polyrizon Ltd. Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC Filing - Form 6-K", "summary": "Polyrizon Ltd. announced that its shareholders approved all proposals at the annual general meeting held on July 13, 2026, including an amended Compensation Policy for executive officers and directors. This policy, valid for three years, ties executive pay to the company's long-t", "url": "https://www.stocktitan.net/sec-filings/PLRZ/6-k-polyrizon-ltd-current-report-foreign-issuer-a93097233b80.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:00:54", "published_display": "13 Jul 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Polyrizon Advances on Test Results", "summary": "Polyrizon Ltd. (NASDAQ: PLRZ) saw its shares rise after announcing successful biocompatibility evaluation program results for its NASARIXTM Allergy Blocker nasal spray. All required biological safety tests met predetermined acceptance criteria, adhering to international standards", "url": "https://www.baystreet.ca/stockstowatch/23587/Polyrizon-Advances-on-Test-Results", "source_name": "Baystreet.ca", "published_at": "2026-07-02T20:10:35", "published_display": "02 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon (PLRZ) clears NASARIX biocompatibility milestone toward first human trial", "summary": "Polyrizon Ltd. announced successful results from its NASARIX\u2122 Allergy Blocker nasal spray's biocompatibility evaluation program. All biological safety tests met acceptance criteria, supporting the product's safety for intranasal use. This achievement marks a significant milestone", "url": "https://www.stocktitan.net/sec-filings/PLRZ/6-k-polyrizon-ltd-current-report-foreign-issuer-fea6fd502581.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:09:36", "published_display": "02 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)", "summary": "Shares of Polyrizon Ltd. (NASDAQ:PLRZ) rose 10% after its NASARIX Allergy Blocker nasal spray successfully passed key biocompatibility testing. The evaluation met all predefined acceptance criteria following international regulatory standards, marking a significant step in the pr", "url": "https://finance.yahoo.com/healthcare/articles/polyrizon-shares-climb-nasarix-passes-122940720.html", "source_name": "Market source", "published_at": "2026-07-02T12:40:47", "published_display": "02 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon completes biocompatibility tests for allergy nasal spray", "summary": "Polyrizon Ltd. announced that its NASARIXTM Allergy Blocker nasal spray successfully met all required biological safety tests under ISO 10993 standards and FDA guidance. This drug-free mucoadhesive nasal spray creates a protective barrier against airborne allergens. The company, ", "url": "https://www.investing.com/news/company-news/polyrizon-completes-biocompatibility-tests-for-allergy-nasal-spray-93CH-4772944", "source_name": "Investing.com", "published_at": "2026-07-02T12:40:47", "published_display": "02 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Announces Successful Results for NASARIX\u2122 Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/polyrizon-announces-successful-results-nasarix-113200858.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T11:32:00+00:00", "published_display": "02 Jul 2026 11:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon\u2019s allergy nasal spray clears safety tests, advancing human trial plans", "summary": "Polyrizon (Nasdaq: PLRZ) announced the successful completion of the biocompatibility evaluation program for its NASARIX\u2122 Allergy Blocker nasal spray. All biological safety tests met predefined acceptance criteria, aligning with international standards such as ISO 10993 and FDA gu", "url": "https://www.stocktitan.net/news/PLRZ/polyrizon-announces-successful-results-for-nasarixtm-3c416x6xme44.html", "source_name": "Stock Titan", "published_at": "2026-07-02T11:40:47", "published_display": "02 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon stock rises on biocompatibility test results By Investing.com", "summary": "Polyrizon Ltd. (NASDAQ:PLRZ) shares rose 10% after announcing successful biocompatibility test results for its NASARIX Allergy Blocker nasal spray. The comprehensive evaluation program met international standards for biological safety, including ISO 10993 series and FDA guidance.", "url": "https://m.za.investing.com/news/stock-market-news/polyrizon-stock-rises-on-biocompatibility-test-results-93CH-4353810?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-02T11:40:47", "published_display": "02 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon stock rises on biocompatibility test results", "summary": "Polyrizon's stock rose 10% after the company announced successful biocompatibility test results for its NASARIX Allergy Blocker nasal spray. The tests, conducted according to international standards, evaluated key biological safety endpoints and support the product's advancement ", "url": "https://www.investing.com/news/stock-market-news/polyrizon-stock-rises-on-biocompatibility-test-results-93CH-4772949", "source_name": "Investing.com", "published_at": "2026-07-02T07:43:00", "published_display": "02 Jul 2026 07:43", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Polyrizon Ltd. \u2013 NASDAQ:PLRZ", "summary": "This article provides a brief snapshot of Polyrizon Ltd. (NASDAQ: PLRZ) financial information, specifically its forward price-to-sales ratio. It appears to be a stub or an incomplete data point from a financial platform like TradingView. The page lacks detailed financial data or ", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRZ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T09:10:13", "published_display": "30 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Receives Approval for Human Trial of Nasarix Nasal Spray for Allergic Rhinitis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/polyrizon-receives-approval-human-trial-134629191.html", "source_name": "MT Newswires", "published_at": "2026-06-29T13:46:29+00:00", "published_display": "29 Jun 2026 13:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon receives IRB approval for nasal spray clinical trial", "summary": "Polyrizon Ltd. has received central institutional review board (IRB) approval to commence its first human clinical trial for NASARIX, a nasal spray designed to block airborne allergens. This approval, granted by the BRANY Institutional Review Board, covers the study protocol and ", "url": "https://www.investing.com/news/company-news/polyrizon-receives-irb-approval-for-nasal-spray-clinical-trial-93CH-4765456", "source_name": "Investing.com", "published_at": "2026-06-29T13:40:31", "published_display": "29 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial", "summary": "Polyrizon Ltd. announced it has received central IRB approval from BRANY Institutional Review Board for its first human clinical trial for NASARIX\u2122, an innovative nasal spray designed to block airborne allergens. This approval marks a significant regulatory milestone, allowing th", "url": "https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/polyrizon-makes-strong-progress-receives-central-irb-approval-for-its-allergy-blocker-clinical-trial/2374891/amp", "source_name": "The Manila Times", "published_at": "2026-06-29T12:40:31", "published_display": "29 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon clears review to start first NASARIX human allergy trial", "summary": "Polyrizon (Nasdaq: PLRZ) has received central IRB approval from BRANY to commence its first human clinical trial for NASARIX\u2122, a nasal spray allergy blocker. The study will compare NASARIX to saline in patients with seasonal allergic rhinitis, evaluating its efficacy, safety, tol", "url": "https://www.stocktitan.net/news/PLRZ/polyrizon-makes-strong-progress-receives-central-irb-approval-for-z2qukiq4h7am.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:40:31", "published_display": "29 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Polyrizon Ltd. \u2013 NASDAQ:PLRZ", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Polyrizon Ltd. (NASDAQ:PLRZ). While the exact value is not provided in the snippet, the article appears to be a financial data presentation page from TradingView. It indicates that the markets were close", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRZ/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:09:24", "published_display": "27 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Polyrizon Ltd. \u2013 NASDAQ:PLRZ", "summary": "This article displays the Enterprise Value to EBITDA forward for Polyrizon Ltd. (NASDAQ: PLRZ) on TradingView. It indicates that the market is closed with no trades. The content also includes various navigation and footer links.", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRZ/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T13:28:21", "published_display": "27 Jun 2026 13:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown section for Polyrizon Ltd (PLRZ). However, it states that relevant data regarding business segments and regional revenue has not yet been disclosed by the company. The page displays current stock information for PLRZ, incl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrz/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:53", "published_display": "18 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Polyrizon Ltd (PLRZ) stock, focusing on its dividend history and stock split events. It states that the company has not distributed any dividends over the past five years but shows a historical merger event on May 22, 2025, with a 250-to-1 rat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrz/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:53", "published_display": "18 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon (Nasdaq: PLRZ) details U.S. patent publication for Trap & Target nasal platform", "summary": "Polyrizon (Nasdaq: PLRZ) announced the publication of a U.S. patent application for its Trap & Target\u2122 mucoadhesive nasal drug delivery platform, patent application No. US 2024/0358741 A1. This technology uses biocompatible mucoadhesive polymers to form a durable film on mucosal ", "url": "https://www.stocktitan.net/sec-filings/PLRZ/6-k-polyrizon-ltd-current-report-foreign-issuer-6a0ff60a4ad8.html", "source_name": "Stock Titan", "published_at": "2026-06-17T19:39:09", "published_display": "17 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform", "summary": "Polyrizon Ltd. announced the publication of a U.S. patent application for its proprietary Trap & Target\u2122 (T&T) mucoadhesive polymer technology platform, designed to enhance nasal drug delivery. This technology aims to improve drug absorption and retention on the nasal mucosa thro", "url": "https://www.manilatimes.net/2026/06/17/tmt-newswire/globenewswire/polyrizon-receives-notice-of-us-patent-publication-for-mucoadhesive-drug-delivery-platform/2367473/amp", "source_name": "The Manila Times", "published_at": "2026-06-17T12:39:53", "published_display": "17 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon patent published for nasal drug-delivery technology", "summary": "Polyrizon (Nasdaq: PLRZ) has announced the publication of its U.S. patent application US 2024/0358741 A1 for its proprietary Trap & Target\u2122 mucoadhesive polymer platform, designed for enhanced nasal drug delivery. This technology aims to improve mucosal retention, drug absorption", "url": "https://www.stocktitan.net/news/PLRZ/polyrizon-receives-notice-of-u-s-patent-publication-for-mucoadhesive-o240b71vs5uk.html", "source_name": "Stock Titan", "published_at": "2026-06-17T12:39:09", "published_display": "17 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Ltd (PLRZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Polyrizon Ltd (PLRZ), covering its support, resistance, indicators, and moving averages. It details various technical indicators like MACD, RSI, and KDJ, alongside moving averages (MA5 to MA200), offering buy, sell, or neutral signals", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrz/technical", "source_name": "TradingKey", "published_at": "2026-06-17T11:39:32", "published_display": "17 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Ltd (PLRZ) Institutional Confidence", "summary": "This article provides institutional confidence data for Polyrizon Ltd (PLRZ), showing a current share price of $13.000, up 13.54%. It details institutional shareholding with Izraeli (Tomer) holding 8.00 shares and notes a previous confidence score of 0.00 with no change. The cont", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrz/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T04:39:10", "published_display": "17 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Polyrizon Ltd (PLRZ), detailing its current stock price and market capitalization. It highlights that no specific earnings per share (EPS), revenue, net profit, or EBIT forecast data is currently available from the company. The page ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrz/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T21:09:22", "published_display": "16 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon (PLRZ) launches NASARIX\u2122 human study to assess nasal residence and aid FDA path", "summary": "Polyrizon Ltd. (PLRZ) has initiated a human performance and characterization study for its NASARIX\u2122 (PL-14) Allergy Blocker. This study, conducted with a European medical center and a CRO, will assess how long the intranasal hydrogel remains in the nasal cavity, providing data cr", "url": "https://www.stocktitan.net/sec-filings/PLRZ/6-k-polyrizon-ltd-current-report-foreign-issuer-68bd318234a5.html", "source_name": "Stock Titan", "published_at": "2026-06-15T19:39:49", "published_display": "15 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon stock surges on human study for allergy blocker By Investing.com", "summary": "Polyrizon Ltd (NASDAQ:PLRZ) shares rose 9.2% after the company announced the start of a human study for its NASARIX allergy blocker. The study aims to evaluate the nasal residence time of NASARIX, which is crucial for assessing its protective barrier function against allergens. T", "url": "https://m.za.investing.com/news/stock-market-news/polyrizon-stock-surges-on-human-study-for-allergy-blocker-93CH-4328613?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-15T14:39:49", "published_display": "15 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Signs Agreements for Nasarix Human Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polyrizon-signs-agreements-nasarix-human-124637428.html", "source_name": "MT Newswires", "published_at": "2026-06-15T12:46:37+00:00", "published_display": "15 Jun 2026 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Advances NASARIX\u2122 Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway", "summary": "Polyrizon, a biotech company, announced a human study for its NASARIX\u2122 (PL-14) Allergy Blocker to evaluate its nasal residence time, a crucial aspect of its protective barrier function. This study, conducted in collaboration with a European medical center and a CRO, will support ", "url": "https://www.manilatimes.net/2026/06/15/tmt-newswire/globenewswire/polyrizon-advances-nasarix-development-with-key-human-study-to-characterize-nasal-residence-time-and-support-fda-regulatory-pathway/2365573", "source_name": "The Manila Times", "published_at": "2026-06-15T12:39:49", "published_display": "15 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon initiates nasal residence time study for allergy blocker", "summary": "Polyrizon Ltd. (NASDAQ:PLRZ) has commenced a human study to evaluate the nasal residence time of its NASARIX allergy blocker product, marking a key clinical development milestone. This study aims to support regulatory submissions, including with the U.S. FDA, by assessing how lon", "url": "https://www.investing.com/news/company-news/polyrizon-initiates-nasal-residence-time-study-for-allergy-blocker-93CH-4741986", "source_name": "Investing.com", "published_at": "2026-06-15T12:39:49", "published_display": "15 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How long can a nasal allergy blocker stay put? New human study aims to find out", "summary": "Polyrizon (Nasdaq: PLRZ) has signed agreements with a leading European university medical center and a specialized CRO to conduct a human study for NASARIX\u2122 (PL-14) Allergy Blocker. The study will measure nasal residence time to determine the duration of the product's protective ", "url": "https://www.stocktitan.net/news/PLRZ/polyrizon-advances-nasarixtm-development-with-key-human-study-to-m9s0lgqiuqra.html", "source_name": "Stock Titan", "published_at": "2026-06-15T11:39:49", "published_display": "15 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polyrizon-receives-notice-european-patent-114700398.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T11:47:00+00:00", "published_display": "10 Jun 2026 11:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Advances Nasarix Study With 3 Major US Trial Sites", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polyrizon-advances-nasarix-study-3-135118546.html", "source_name": "MT Newswires", "published_at": "2026-06-08T13:51:18+00:00", "published_display": "08 Jun 2026 13:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX\u2122 Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polyrizon-makes-strong-clinical-progress-132500675.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T13:25:00+00:00", "published_display": "08 Jun 2026 13:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Polyrizon raises $3.5M in stock sale for working capital", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPRk1RUWdzdDV1MHd3NkZlMEVXbHFyaldHZV9GU1l1LUF5UnBkNXdtdWxDek1FWGlUTEFpcmp6MW4wOVNxZU56QVUxS1R1YWtHYW9mOHZ1MzdiLWt2N1JHUzNBeUpVak1ROWYyTUZUN3VVQXNfUk5vT010NFdWTy0wSkszbmFFNm9HY0FXeHYyYVJrdlNmRUxlNFgxMHNlZk9UUkI1NVdHZEprRUJGbnpDVUdVSEpuS3A2WWFlMDl4NGQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We're Keeping An Eye On Polyrizon's (NASDAQ:PLRZ) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLRZ Stock Price and Chart \u2014 NASDAQ:PLRZ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9mSmtCaHhlaV8ybGRGRGdnbkY1b2JXQVRZUXhGckxBSjhORTcwa2NiSk9SaGgxb1BsN3dJcjFtdnpFb2ZlbTczYmNKWTZkaGhhNWxDdW5JV3d3aldX?oc=5", "source_name": "TradingView", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon (Nasdaq: PLRZ) scales up PL-14 nasal spray production for 2026 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOazd0QlZTOXVHVkhEYzYxcjV6WW5BRFo3cUJHRDVoeGZ4dmJKWDdVdklia1VoeGQ2eTRBUmxhZ2dFRGhBczRrYUJSQ3NubjVFcGxITVEydkk0a0lIa19EU0UxYUFlZGNMTFBfeWxHZ203UXFHN09vYTB0NUNQbVRpekRUTlZ2eldxWjRZM0xHTDU2MktQQkFlUTc0bWxpeURjWm5fdk5IbUVYcHVqcGJKOWh1bFRKNExL?oc=5", "source_name": "Stock Titan", "published_at": "2025-12-02T08:00:00+00:00", "published_display": "02 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC Filing - Form 6-K", "summary": "Polyrizon Ltd. announced that its shareholders approved all proposals at the annual general meeting held on July 13, 2026, including an amended Compensation Policy for executive officers and directors. This policy, valid for three years, ties executive pay to the company's long-t", "url": "https://www.stocktitan.net/sec-filings/PLRZ/6-k-polyrizon-ltd-current-report-foreign-issuer-a93097233b80.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:00:54", "published_display": "13 Jul 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Advances on Test Results", "summary": "Polyrizon Ltd. (NASDAQ: PLRZ) saw its shares rise after announcing successful biocompatibility evaluation program results for its NASARIXTM Allergy Blocker nasal spray. All required biological safety tests met predetermined acceptance criteria, adhering to international standards", "url": "https://www.baystreet.ca/stockstowatch/23587/Polyrizon-Advances-on-Test-Results", "source_name": "Baystreet.ca", "published_at": "2026-07-02T20:10:35", "published_display": "02 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon (PLRZ) clears NASARIX biocompatibility milestone toward first human trial", "summary": "Polyrizon Ltd. announced successful results from its NASARIX\u2122 Allergy Blocker nasal spray's biocompatibility evaluation program. All biological safety tests met acceptance criteria, supporting the product's safety for intranasal use. This achievement marks a significant milestone", "url": "https://www.stocktitan.net/sec-filings/PLRZ/6-k-polyrizon-ltd-current-report-foreign-issuer-fea6fd502581.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:09:36", "published_display": "02 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)", "summary": "Shares of Polyrizon Ltd. (NASDAQ:PLRZ) rose 10% after its NASARIX Allergy Blocker nasal spray successfully passed key biocompatibility testing. The evaluation met all predefined acceptance criteria following international regulatory standards, marking a significant step in the pr", "url": "https://finance.yahoo.com/healthcare/articles/polyrizon-shares-climb-nasarix-passes-122940720.html", "source_name": "Market source", "published_at": "2026-07-02T12:40:47", "published_display": "02 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon completes biocompatibility tests for allergy nasal spray", "summary": "Polyrizon Ltd. announced that its NASARIXTM Allergy Blocker nasal spray successfully met all required biological safety tests under ISO 10993 standards and FDA guidance. This drug-free mucoadhesive nasal spray creates a protective barrier against airborne allergens. The company, ", "url": "https://www.investing.com/news/company-news/polyrizon-completes-biocompatibility-tests-for-allergy-nasal-spray-93CH-4772944", "source_name": "Investing.com", "published_at": "2026-07-02T12:40:47", "published_display": "02 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Announces Successful Results for NASARIX\u2122 Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/polyrizon-announces-successful-results-nasarix-113200858.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T11:32:00+00:00", "published_display": "02 Jul 2026 11:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon\u2019s allergy nasal spray clears safety tests, advancing human trial plans", "summary": "Polyrizon (Nasdaq: PLRZ) announced the successful completion of the biocompatibility evaluation program for its NASARIX\u2122 Allergy Blocker nasal spray. All biological safety tests met predefined acceptance criteria, aligning with international standards such as ISO 10993 and FDA gu", "url": "https://www.stocktitan.net/news/PLRZ/polyrizon-announces-successful-results-for-nasarixtm-3c416x6xme44.html", "source_name": "Stock Titan", "published_at": "2026-07-02T11:40:47", "published_display": "02 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon stock rises on biocompatibility test results By Investing.com", "summary": "Polyrizon Ltd. (NASDAQ:PLRZ) shares rose 10% after announcing successful biocompatibility test results for its NASARIX Allergy Blocker nasal spray. The comprehensive evaluation program met international standards for biological safety, including ISO 10993 series and FDA guidance.", "url": "https://m.za.investing.com/news/stock-market-news/polyrizon-stock-rises-on-biocompatibility-test-results-93CH-4353810?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-02T11:40:47", "published_display": "02 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon stock rises on biocompatibility test results", "summary": "Polyrizon's stock rose 10% after the company announced successful biocompatibility test results for its NASARIX Allergy Blocker nasal spray. The tests, conducted according to international standards, evaluated key biological safety endpoints and support the product's advancement ", "url": "https://www.investing.com/news/stock-market-news/polyrizon-stock-rises-on-biocompatibility-test-results-93CH-4772949", "source_name": "Investing.com", "published_at": "2026-07-02T07:43:00", "published_display": "02 Jul 2026 07:43", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Polyrizon Ltd. \u2013 NASDAQ:PLRZ", "summary": "This article provides a brief snapshot of Polyrizon Ltd. (NASDAQ: PLRZ) financial information, specifically its forward price-to-sales ratio. It appears to be a stub or an incomplete data point from a financial platform like TradingView. The page lacks detailed financial data or ", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRZ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T09:10:13", "published_display": "30 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Receives Approval for Human Trial of Nasarix Nasal Spray for Allergic Rhinitis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/polyrizon-receives-approval-human-trial-134629191.html", "source_name": "MT Newswires", "published_at": "2026-06-29T13:46:29+00:00", "published_display": "29 Jun 2026 13:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon receives IRB approval for nasal spray clinical trial", "summary": "Polyrizon Ltd. has received central institutional review board (IRB) approval to commence its first human clinical trial for NASARIX, a nasal spray designed to block airborne allergens. This approval, granted by the BRANY Institutional Review Board, covers the study protocol and ", "url": "https://www.investing.com/news/company-news/polyrizon-receives-irb-approval-for-nasal-spray-clinical-trial-93CH-4765456", "source_name": "Investing.com", "published_at": "2026-06-29T13:40:31", "published_display": "29 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial", "summary": "Polyrizon Ltd. announced it has received central IRB approval from BRANY Institutional Review Board for its first human clinical trial for NASARIX\u2122, an innovative nasal spray designed to block airborne allergens. This approval marks a significant regulatory milestone, allowing th", "url": "https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/polyrizon-makes-strong-progress-receives-central-irb-approval-for-its-allergy-blocker-clinical-trial/2374891/amp", "source_name": "The Manila Times", "published_at": "2026-06-29T12:40:31", "published_display": "29 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon clears review to start first NASARIX human allergy trial", "summary": "Polyrizon (Nasdaq: PLRZ) has received central IRB approval from BRANY to commence its first human clinical trial for NASARIX\u2122, a nasal spray allergy blocker. The study will compare NASARIX to saline in patients with seasonal allergic rhinitis, evaluating its efficacy, safety, tol", "url": "https://www.stocktitan.net/news/PLRZ/polyrizon-makes-strong-progress-receives-central-irb-approval-for-z2qukiq4h7am.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:40:31", "published_display": "29 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Polyrizon Ltd. \u2013 NASDAQ:PLRZ", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Polyrizon Ltd. (NASDAQ:PLRZ). While the exact value is not provided in the snippet, the article appears to be a financial data presentation page from TradingView. It indicates that the markets were close", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRZ/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T20:09:24", "published_display": "27 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Polyrizon Ltd. \u2013 NASDAQ:PLRZ", "summary": "This article displays the Enterprise Value to EBITDA forward for Polyrizon Ltd. (NASDAQ: PLRZ) on TradingView. It indicates that the market is closed with no trades. The content also includes various navigation and footer links.", "url": "https://www.tradingview.com/symbols/NASDAQ-PLRZ/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T13:28:21", "published_display": "27 Jun 2026 13:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown section for Polyrizon Ltd (PLRZ). However, it states that relevant data regarding business segments and regional revenue has not yet been disclosed by the company. The page displays current stock information for PLRZ, incl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrz/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:53", "published_display": "18 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Polyrizon Ltd (PLRZ) stock, focusing on its dividend history and stock split events. It states that the company has not distributed any dividends over the past five years but shows a historical merger event on May 22, 2025, with a 250-to-1 rat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrz/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:53", "published_display": "18 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon (Nasdaq: PLRZ) details U.S. patent publication for Trap & Target nasal platform", "summary": "Polyrizon (Nasdaq: PLRZ) announced the publication of a U.S. patent application for its Trap & Target\u2122 mucoadhesive nasal drug delivery platform, patent application No. US 2024/0358741 A1. This technology uses biocompatible mucoadhesive polymers to form a durable film on mucosal ", "url": "https://www.stocktitan.net/sec-filings/PLRZ/6-k-polyrizon-ltd-current-report-foreign-issuer-6a0ff60a4ad8.html", "source_name": "Stock Titan", "published_at": "2026-06-17T19:39:09", "published_display": "17 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform", "summary": "Polyrizon Ltd. announced the publication of a U.S. patent application for its proprietary Trap & Target\u2122 (T&T) mucoadhesive polymer technology platform, designed to enhance nasal drug delivery. This technology aims to improve drug absorption and retention on the nasal mucosa thro", "url": "https://www.manilatimes.net/2026/06/17/tmt-newswire/globenewswire/polyrizon-receives-notice-of-us-patent-publication-for-mucoadhesive-drug-delivery-platform/2367473/amp", "source_name": "The Manila Times", "published_at": "2026-06-17T12:39:53", "published_display": "17 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon patent published for nasal drug-delivery technology", "summary": "Polyrizon (Nasdaq: PLRZ) has announced the publication of its U.S. patent application US 2024/0358741 A1 for its proprietary Trap & Target\u2122 mucoadhesive polymer platform, designed for enhanced nasal drug delivery. This technology aims to improve mucosal retention, drug absorption", "url": "https://www.stocktitan.net/news/PLRZ/polyrizon-receives-notice-of-u-s-patent-publication-for-mucoadhesive-o240b71vs5uk.html", "source_name": "Stock Titan", "published_at": "2026-06-17T12:39:09", "published_display": "17 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Ltd (PLRZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Polyrizon Ltd (PLRZ), covering its support, resistance, indicators, and moving averages. It details various technical indicators like MACD, RSI, and KDJ, alongside moving averages (MA5 to MA200), offering buy, sell, or neutral signals", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrz/technical", "source_name": "TradingKey", "published_at": "2026-06-17T11:39:32", "published_display": "17 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Ltd (PLRZ) Institutional Confidence", "summary": "This article provides institutional confidence data for Polyrizon Ltd (PLRZ), showing a current share price of $13.000, up 13.54%. It details institutional shareholding with Izraeli (Tomer) holding 8.00 shares and notes a previous confidence score of 0.00 with no change. The cont", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrz/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T04:39:10", "published_display": "17 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Polyrizon Ltd (PLRZ), detailing its current stock price and market capitalization. It highlights that no specific earnings per share (EPS), revenue, net profit, or EBIT forecast data is currently available from the company. The page ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-plrz/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T21:09:22", "published_display": "16 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon (PLRZ) launches NASARIX\u2122 human study to assess nasal residence and aid FDA path", "summary": "Polyrizon Ltd. (PLRZ) has initiated a human performance and characterization study for its NASARIX\u2122 (PL-14) Allergy Blocker. This study, conducted with a European medical center and a CRO, will assess how long the intranasal hydrogel remains in the nasal cavity, providing data cr", "url": "https://www.stocktitan.net/sec-filings/PLRZ/6-k-polyrizon-ltd-current-report-foreign-issuer-68bd318234a5.html", "source_name": "Stock Titan", "published_at": "2026-06-15T19:39:49", "published_display": "15 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon stock surges on human study for allergy blocker By Investing.com", "summary": "Polyrizon Ltd (NASDAQ:PLRZ) shares rose 9.2% after the company announced the start of a human study for its NASARIX allergy blocker. The study aims to evaluate the nasal residence time of NASARIX, which is crucial for assessing its protective barrier function against allergens. T", "url": "https://m.za.investing.com/news/stock-market-news/polyrizon-stock-surges-on-human-study-for-allergy-blocker-93CH-4328613?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-15T14:39:49", "published_display": "15 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Signs Agreements for Nasarix Human Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polyrizon-signs-agreements-nasarix-human-124637428.html", "source_name": "MT Newswires", "published_at": "2026-06-15T12:46:37+00:00", "published_display": "15 Jun 2026 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Advances NASARIX\u2122 Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway", "summary": "Polyrizon, a biotech company, announced a human study for its NASARIX\u2122 (PL-14) Allergy Blocker to evaluate its nasal residence time, a crucial aspect of its protective barrier function. This study, conducted in collaboration with a European medical center and a CRO, will support ", "url": "https://www.manilatimes.net/2026/06/15/tmt-newswire/globenewswire/polyrizon-advances-nasarix-development-with-key-human-study-to-characterize-nasal-residence-time-and-support-fda-regulatory-pathway/2365573", "source_name": "The Manila Times", "published_at": "2026-06-15T12:39:49", "published_display": "15 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon initiates nasal residence time study for allergy blocker", "summary": "Polyrizon Ltd. (NASDAQ:PLRZ) has commenced a human study to evaluate the nasal residence time of its NASARIX allergy blocker product, marking a key clinical development milestone. This study aims to support regulatory submissions, including with the U.S. FDA, by assessing how lon", "url": "https://www.investing.com/news/company-news/polyrizon-initiates-nasal-residence-time-study-for-allergy-blocker-93CH-4741986", "source_name": "Investing.com", "published_at": "2026-06-15T12:39:49", "published_display": "15 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How long can a nasal allergy blocker stay put? New human study aims to find out", "summary": "Polyrizon (Nasdaq: PLRZ) has signed agreements with a leading European university medical center and a specialized CRO to conduct a human study for NASARIX\u2122 (PL-14) Allergy Blocker. The study will measure nasal residence time to determine the duration of the product's protective ", "url": "https://www.stocktitan.net/news/PLRZ/polyrizon-advances-nasarixtm-development-with-key-human-study-to-m9s0lgqiuqra.html", "source_name": "Stock Titan", "published_at": "2026-06-15T11:39:49", "published_display": "15 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polyrizon-receives-notice-european-patent-114700398.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T11:47:00+00:00", "published_display": "10 Jun 2026 11:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Advances Nasarix Study With 3 Major US Trial Sites", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polyrizon-advances-nasarix-study-3-135118546.html", "source_name": "MT Newswires", "published_at": "2026-06-08T13:51:18+00:00", "published_display": "08 Jun 2026 13:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX\u2122 Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/polyrizon-makes-strong-clinical-progress-132500675.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T13:25:00+00:00", "published_display": "08 Jun 2026 13:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon raises $3.5M in stock sale for working capital", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPRk1RUWdzdDV1MHd3NkZlMEVXbHFyaldHZV9GU1l1LUF5UnBkNXdtdWxDek1FWGlUTEFpcmp6MW4wOVNxZU56QVUxS1R1YWtHYW9mOHZ1MzdiLWt2N1JHUzNBeUpVak1ROWYyTUZUN3VVQXNfUk5vT010NFdWTy0wSkszbmFFNm9HY0FXeHYyYVJrdlNmRUxlNFgxMHNlZk9UUkI1NVdHZEprRUJGbnpDVUdVSEpuS3A2WWFlMDl4NGQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Polyrizon's (NASDAQ:PLRZ) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PLRZ Stock Price and Chart \u2014 NASDAQ:PLRZ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9mSmtCaHhlaV8ybGRGRGdnbkY1b2JXQVRZUXhGckxBSjhORTcwa2NiSk9SaGgxb1BsN3dJcjFtdnpFb2ZlbTczYmNKWTZkaGhhNWxDdW5JV3d3aldX?oc=5", "source_name": "TradingView", "published_at": "2025-12-04T08:00:00+00:00", "published_display": "04 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Polyrizon (Nasdaq: PLRZ) scales up PL-14 nasal spray production for 2026 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOazd0QlZTOXVHVkhEYzYxcjV6WW5BRFo3cUJHRDVoeGZ4dmJKWDdVdklia1VoeGQ2eTRBUmxhZ2dFRGhBczRrYUJSQ3NubjVFcGxITVEydkk0a0lIa19EU0UxYUFlZGNMTFBfeWxHZ203UXFHN09vYTB0NUNQbVRpekRUTlZ2eldxWjRZM0xHTDU2MktQQkFlUTc0bWxpeURjWm5fdk5IbUVYcHVqcGJKOWh1bFRKNExL?oc=5", "source_name": "Stock Titan", "published_at": "2025-12-02T08:00:00+00:00", "published_display": "02 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 82, "total_relevant": 46, "sentiment_summary": {"positive": 22, "negative": 3, "neutral": 21, "score": 61, "total": 46, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 72, "events": [{"event": "general", "label": "Market update", "weight": 8.25, "count": 15}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.4, "count": 8}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 22, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 14.65, "latest_week": "2026-07-10", "one_week_move": 6.2, "four_week_move": 31.6, "twelve_week_move": 28.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.278782, "market_dynamics_buy_signal": false, "relative_strength": 21.011986, "fair_value_gap": -96.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 51.4963, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.2% over one week, +31.6% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "Market source", "count": 7}, {"label": "TradingView", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "The Manila Times", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 37}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 17}, {"label": "Market update", "count": 15}, {"label": "Regulatory and legal", "count": 8}, {"label": "Analyst action", "count": 3}, {"label": "Guidance", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "61/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "37", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.2% over one week, +31.6% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC Filing - Form 6-K"}], "updated_at": "2026-07-18T01:15:12.358976+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}